[Coincidence of melanoma growth and immune status? Virus antigens as a parameter (author's transl)].
Antibody titer determinations against Epstein-Barr virus were carried out after primary operation in 51 patients with malignant melanoma in an observation period of 18 months. A coincidence of tumor growth and reduced immune defense was established. The antibody titer thus serves as a parameter for assessment of immune behavior.
D000328:Adult; D000368:Aged; D000620:Aminoimidazole Carboxamide / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000032:analysis*; D001500:BCG Vaccine / Q000627:therapeutic use; D005260:Female; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007428:Intradermal Tests; D008297:Male; D008545:Melanoma / Q000276:immunology* / Q000601:surgery; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging
D000914:Antibodies, Viral; D001500:BCG Vaccine; D000620:Aminoimidazole Carboxamide
Koinzidenz von Melanom-Wachstum und Immunstatus? Virusantigene als Parameter.